Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Nihon Chouzai to Make Choseido Subsidiary, to Sell Its Products Through Nihon Generic
April 4, 2013
- Plavix Rises to 3rd Place in Domestic Ethical Drug Market in 2012, Could Take No. 1 Spot This Year
April 4, 2013
- MSD Reports Downturn in Profits for 2012 Despite 2.7% Growth in Sales
April 3, 2013
- AZ K.K. Reports 5.1% Decline in 2012 Sales; Sales of Omepral and Casodex Down
April 3, 2013
- Bayer Yakuhin Reports Nearly 20% Drop in Operating Profit Despite Growth in Sales of Zetia
April 3, 2013
- Abbott Japan Names Mr Sakamoto as President, Mr Honda as Vice President
April 3, 2013
- Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
- Kaketsuken also Files NDA for Cell Culture-Based New Influenza Vaccine
April 3, 2013
- Taiho Assigns 54 Oncology MRs according to Cancer Type
April 3, 2013
- AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
- DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
- Gabriel Baertschi Takes Over as President of AZ K.K.
April 2, 2013
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
- Dainippon Sumitomo Pharma Ties Up with Venture Company to Commercialize iPS Cell Therapy for Retinal Disease
April 1, 2013
- EMA Accepts Shionogi’s MAA for Ospemifene
April 1, 2013
- Asklep to Establish Joint Venture Company with US CRO ReSearch Pharmaceutical Services
April 1, 2013
- GSK's Operating Profit Down 22% in 2012 due to Cervarix Sales Drop
March 29, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…